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Objectives: Cognitive	 impairment	 is	 frequent	 in	multiple	sclerosis	 (MS)	as	approxi-
mately half of the patients manifest some degree of cognitive impairment. The Brief 
International	 Cognitive	 Assessment	 for	Multiple	 Sclerosis	 (BICAMS)	 has	 been	 de-
signed for brief cognitive evaluation. The purpose of the study was to validate the 




the	Fatigue	Scale	 for	Motor	and	Cognitive	Functions	 (FSMC)	 twice,	approximately	
within nine days.
Results: MS	patients	scored	markedly	lower	than	the	HCs	on	each	of	the	three	tests	











the	 FSMC	 proved	 useful	 tools	 in	 approaching	 concerns	 related	 to	 cognition	 and	
fatigue.
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1  | INTRODUC TION
Cognitive deficits are a common manifestation in multiple scle-
rosis	 (MS)	 occurring	 in	 about	 50%–	60%	 of	 patients	 (Sumowski	
et	al.,	(2018)).	Slowed	information	processing	as	well	as	memory	and	
learning dysfunction are regarded as the most frequent cognitive 
deficits	 (Benedict	 et	 al.,	 2020;	 Sumowski	 et	 al.,	 2018).	 Slowed	 in-
formation processing speed in particular is thought to be the core 
feature	 of	 cognitive	 decline	 in	 MS.	 The	 functional	 consequences	
of	MS-	related	cognitive	 impairment	can	be	striking	 (Hämäläinen	&	
Rosti-	Otajärvi,	2014).	Cognitive	deficits	may	have	effects	on	phys-






Despite the high frequency and obvious negative impact on 
functioning,	 cognitive	 impairment	 often	 remains	 undiagnosed;	 in-
visible	 symptoms,	 especially	 mild	 cognitive	 impairments,	 are	 not	
observed	during	routine	neurological	examinations.	To	improve	the	
detection	 of	 cognitive	 impairments	 and	 to	make	 follow-	up	 easier,	
brief	assessment	tools	have	been	suggested	for	routine	use.	An	in-
ternational	 expert	 committee	agreed	on	a	 short	battery,	 the	Brief	
International	Cognitive	Assessment	for	Multiple	Sclerosis	(BICAMS),	
which is considered a valid and reliable measure of cognitive func-
tioning	in	MS	when	comprehensive	neuropsychological	assessment	





evaluating visual memory and learning.
In	 clinical	 practice,	 self-	reports	 provide	 an	 important	 source	
of	 information	 on	 subjective	 symptoms.	 The	 Multiple	 Sclerosis	
Neuropsychological	Questionnaire	(MSNQ)	(Benedict	et	al.,	2013)	
has	been	used	to	assess	cognition-	related	concerns.	Furthermore,	
the	 Fatigue	 Scale	 for	 Cognitive	 and	 Motor	 Functions	 (FSMC)	
(Penner	 et	 al.,	 2009)	 offers	 a	 possibility	 to	 not	 only	 evaluate	
subjective overall fatigue but also the cognitive and motor com-
ponents	 of	 the	 symptom.	 Self-	reports	 are	 valuable	 especially	 in	
cases	where	objective	assessment	is	not	available,	and	they	serve	
as	a	way	 to	approach	a	delicate	 topic.	However,	 self-	reports	are	
vulnerable to different sources of errors and require validation 
before use in new populations and as new translations. Whereas 
self- perceived cognitive and fatigue symptoms have been found to 
be	associated	with	depression	scores,	controlling	for	mood	state	
is necessary.










ing 2018 to 2019 from Masku Neurological Rehabilitation Centre 
in	Finland.	The	study	was	approved	by	the	Ethical	Committee	of	
the	 Hospital	 District	 of	 Southwest	 Finland	 and	 was	 performed	
in	conformance	with	 the	Declaration	of	Helsinki	 (World	Medical	









sion	 criteria.	 After	 this	 prescreening,	 73	 patients	with	MS	were	
informed	 of	 the	 study	 and	 eight	 of	 them	 refused	 to	 participate,	
mainly	 due	 to	 unwillingness	 to	 be	 assessed.	HCs	were	 recruited	
from the personnel of the rehabilitation center as well as their 
relatives	and	friends	following	the	inclusion	and	exclusion	criteria	










The study procedures followed the recommendations for the 
BICAMS	national	validation	including	(a)	standardization	and	trans-
lation	 of	 test	 stimuli,	 (b)	 standardization	 and	 translation	 of	 test	
K E Y W O R D S
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information processing. The test consists of a sheet with nine sym-




the	 instructions	was	 employed,	 and	 same	 version	 of	 the	 test	was	
used in both assessments. The number of orally given correct an-
swers during 90 s served as the dependent variable.
2.4 | CVLT- II
The	California	Verbal	Learning	Test	 II	 (CVLT-	II;	6)	measures	verbal	
learning. The immediate recall consists of five learning trials of a 
word	list	of	four	words	each	in	four	semantic	categories.	The	exam-
iner reads the words aloud at a steady pace during 20 s. The partici-









on a sheet of paper. Participants are given 10 s to look at the symbols 
and are then asked to draw as many symbols as they can recall in the 
right order on an empty sheet of paper. Performance is scored on ac-
curacy	and	location	with	0–	2	points	per	symbol.	The	task	is	repeated	
three	 times.	For	 the	present	 study,	 the	existing	Finnish	version	of	
the test and the instructions were employed. There are several al-
ternative forms of the test; version 1 was used during baseline and 
version 2 during retest. The sum score on the three trials served as 
the dependent variable.
2.6 | 2.3. Self- rating questionnaires
Subjective	cognitive	complaints	were	assessed	by	using	the	Finnish	
version	of	 the	MSNQ	(Benedict	et	al.,	2013),	which	consists	of	15	
questions assessing cognitive restrictions with the scale ranging 
from	0	 (never)	 to	4	 (frequently).	The	 total	 score	served	as	 the	de-
pendent	 variable.	 Subjective	 feelings	 of	 fatigue	 were	 evaluated	
with	the	FSMC	(Delis	et	al.,	2000).	The	questionnaire	consists	of	20	
statements related to motor and cognitive aspects of fatigue with 
the	scale	 ranging	 from	1	 (totally	disagree)	 to	5	 (totally	agree).	The	




Groups	 were	 compared	 with	 the	 Mann–	Whitney	 U test and the 
Wilcoxon	 test	 for	 continuous	 and	 ordered	 variables	 and	 the	 chi-	
square test for binary variables. Results were considered statisti-
cally significant when p <.05,	without	correction	for	multiple	testing.	




tions.	 The	 test–	retest	 reliability	 was	 considered	 acceptable	 when	
the correlation coefficient was greater than 0.70. Performance on 
individual	tests	was	considered	impaired	if	at	or	below	the	−1.5	SD 
level	of	the	HC	distribution	(Sumowski	et	al.,	2018).	Overall	cognitive	
performance was defined as impaired if performance at least on one 
test	of	 the	BICAMS	was	 impaired.	The	 internal	consistency	of	 the	
MSNQ	and	the	FSMC	questionnaires	was	evaluated	with	Cronbach's	
alpha,	 with	 0.70	 considered	 acceptable.	 Statistical	 analyses	 were	
performed	with	IBM	SPSS	24.0.
2.8 | Results
The background variables of the study groups are reported in 
Table 1. The mean interval of the baseline and the retest was 9.0 (SD 




ability	 (4–	6.5),	 and	11%	were	 restricted	 to	a	wheelchair	 (Benedict	
et	al.,	1997;	Benedict	et	al.,	2013;	Penner	et	al.,	2009).	A	majority	of	
the	patients	 (62%)	had	a	 relapsing–	remitting	 and	a	minority	 (38%)	




test	 (Table	2).	The	between-	groups	Cohen's	ds	were	 from	0.69	 to	
1.20	showing	medium	to	very	large	effect	sizes	(Cohen,	1988).	Both	
groups	showed	practice	effects	as	the	performance	at	the	retest	ex-
ceeded that observed at the baseline.
At	baseline,	60%	(39/65)	of	the	patients	were	impaired	on	at	least	
one	of	the	three	BICAMS	tests.	Of	the	patients,	29%	(19/65)	showed	
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at the baseline and at the retest as seen as significantly higher 
scores	on	the	MSNQ	and	the	FSMC	(Table	4).	The	between-	groups	
Cohen's	ds	were	over	1.0	showing	at	least	large	effect	sizes	(Cohen,	
1988).	 Cronbach's	 alpha	 for	 the	 MSNQ	 was	 0.94,	 for	 the	 whole	
FSMC	0.98,	and	for	both	the	cognitive	and	the	motor	subscales	of	
the	FSMC	0.96.




(n = 45) p
Female;	%	(n) 71.0	(46) 71.0	(32) 0.97
Age,	years;	mean	(SD) 50.9	(8.8) 49.4	(12.6) 0.35





Disease	duration,	years	since	symptoms;	mean	(SD) 21.9	(11.2) — 
Disease	duration,	years	since	diagnosis;	mean	(SD) 15.9	(9.8) — 
PREDSS	score	(range	0–	9);	mean	(SD) 4.8	(2.0) — 






mean (SD) d (CLES) p
SDMT	correct
Baseline 41.9	(11.8) 54.6	(8.3) 1.20	(0.80) <0.001
Retest 45.7	(12.9) 59.5	(10.1) 1.16	(0.79) <0.001
CVLT-	II	total	score
Baseline 43.0	(11.5) 51.3	(10.7) 0.75	(0.70) <0.001
Retest 51.6	(13.8) 60.8	(12.0) 0.70	(0.69) <0.001
BVMT-	R	total	score
Baseline 19.2	(8.0) 24.7	(6.8) 0.73	(0.70) <0.001
Retest 20.8	(7.2) 25.3	(5.4) 0.69	(0.69) <0.001
Abbreviations:	BVMT-	R,	Brief	Visual	Memory	Test-	Revised;	CLES,	The	Common	Language	Effect	
Size	statistic;	CVLT-	II,	California	Verbal	Learning	Test-	II;	d,	Cohen's	d with pooled standard 
deviation;	SDMT,	Symbol	Digit	Modalities	Test.




TA B L E  3  MS	patients	performing	at	least	1.5	standard	deviations	(SD)	below	the	mean	of	the	HCs	at	baseline
Test
Cut- off (score equal to or more than 1.5 
SD below the mean of the HCs)
MS patients impaired, performance at or 
under the cut- off % (n)
MS patients impaired also on another 
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Correlations	 between	 the	 study	 variables,	 the	 BICAMS,	 the	
MSNQ,	the	FSMC,	and	the	CES-	D	are	presented	in	Table	5.	Of	the	
MS	patients,	46%	(30/65)	reported	subjective	cognitive	complaints	
















Test–	retest	 reliability	 results	 are	 reported	 in	 Table	 6.	 All	 the	
test–	retest	 correlations	 for	 the	whole	 study	 sample	as	well	 as	 for	
the	MS	patients	were	over	0.70	(all	p <	.001).	In	the	HC	group,	the	




population	 with	 MS	 by	 employing	 the	 validation	 procedure	 sug-




MS	 patients	 performed	 significantly	 worse	 than	 the	 HCs	 on	
each	three	tests	of	the	BICAMS.	On	the	SDMT,	the	difference	be-
tween	the	HC	and	the	MS	group	at	baseline	was	almost	13	points	





tween	 the	 two	groups	was	more	 than	eight	points	on	 the	CVLT-	II	
at	 the	 baseline	 in	 the	 present	 study,	 while	 it	 has	 varied	 between	
one	to	10	points	 in	other	studies	 (Costers	et	al.,	2017;	Dusankova	
et	al.,	2012;	Giedraitiene	et	al.,	2015;	Niino	et	al.,	2017;	O’Connell	






Niino	 et	 al.,	 2017;	 O’Connell	 et	 al.,	 2015;	 Ozakbas	 et	 al.,	 2017;	
Polychroniadou	et	al.,	2016;	Sandi	et	al.,	2015;	Spedo	et	al.,	2015;	
Vanotti	et	al.,	2016;	Walker	et	al.,	2016).	Our	participants	were	older	




the	MS	 patients	 and	 the	HCs	 as	well	 as	 the	 lower	 overall	 perfor-
mance	compared	with	most	of	the	other	BICAMS	studies.
Both groups showed practice effects on the tests of the 
BICAMS.	The	performances	at	the	retest	exceeded	those	observed	
at the baseline in both groups. The differences in practice effects 
Test
MS patients mean 
(SD)
Healthy controls 
mean (SD) d (CLES) p
MSNQ-	T
Baseline 23.9	(11.1) 13.8	(6.6) 1.06	(0.77) <0.001
Retest 25.4	(11.1) 12.2	(6.3) 1.39	(0.84) <0.001
FSMC-	T
Baseline 49.2	(16.7) 9.3	(8.4) 2.87	(0.98) <0.001
Retest 48.2	(16.7) 8.8	(8.4) 2.82	(0.98) <0.001
FSMC-	M
Baseline 25.7	(8.2) 3.9	(4.4) 3.16	(0.99) <0.001
Retest 25.3	(8.0) 3.6	(3.5) 3.29	(0.99) <0.001
FSMC-	C
Baseline 23.5	(9.9) 5.4	(4.5) 2.22	(0.94) <0.001
Retest 22.8	(9.8) 5.2	(5.5) 2.11	(0.93) <0.001




TA B L E  4  The	results	of	MS	patients	
and	HCs	on	the	MSNQ	and	the	FSMC	
during baseline and retest (SD = standard 
deviation)
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between	 the	 groups	were	 small.	 The	 same	 versions	 of	 the	 SDMT	
and	 the	CVLT-	II	 tests	were	 used	 for	 the	 repeated	measurements.	
Instead,	parallel	versions	were	used	for	 the	BVMT-	R.	The	practice	
effects can be suggested to be more evident when same test version 







the fact that their patients were 11 years younger and slightly more 
educated compared with ours. The difference between the baseline 
and	the	retest	in	the	Italian	study	was	4.1	points	for	the	SDMT,	8.0	
points	 for	 the	CVLT-	II,	and	3.1	points	 for	 the	BVMT-	R.	The	differ-
ences were relatively similar to those observed in the present study 
despite	the	bigger	difference	in	the	BVMT-	R	which	is	probably	ex-
plained by the use of same test version twice in the Italian study. 
Furthermore,	 linguistic	 and	 cultural	 differences	 that	 occur	 in	 test	
translations as well as differences in the time the tests are repeated 
may	explain	the	subtle	differences	in	the	test	results	between	differ-
ent language versions.
Altogether	60%	of	 the	patients	 showed	 impaired	performance	
on	at	least	one	of	the	BICAMS	tests.	This	finding	is	well	in	line	with	
the	 known	 frequency	 of	 cognitive	 impairment	 in	 MS	 (Benedict	




(Sandi	 et	 al.,	 2015).	 The	 Finnish	 version	 of	 the	BICAMS	 seems	 to	
tap	MS-	related	cognitive	impairment	at	a	satisfactory	level	and,	thus,	
can	be	considered	as	a	useful	and	valid	measure	to	identify	MS	pa-
tients who may have cognitive impairments.
From	the	three	single	tests	of	the	Finnish	version	of	the	BICAMS,	
the	SDMT	was	the	most	sensitive	followed	by	the	BVMT-	R	and	the	











The	 test–	retest	 reliability	 of	 the	 BICAMS	 was	 evaluated	 with	
the	 correlation	 coefficients.	 For	 the	SDMT	as	well	 as	 the	CVLT-	II,	
the	correlations	 for	 the	whole	study	sample	as	well	as	 for	 the	MS	
group were >	 0.80	 indicating	 good	 test–	retest	 reliability.	 For	 the	
BVMT-	R,	the	correlation	was	>	0.70	showing	adequate	test–	retest	
reliability. These results are in line with the findings from the other 
BICAMS	validation	studies	in	which	the	correlations	for	the	SDMT	
and	 the	 CVLT-	II	 have	 been	 higher	 than	 those	 for	 the	 BVMT-	R	




SDMT CVLT- II BVMT- R MSNQ FSMC- T FSMC- M FSMC- C
CVLT-	II 0.46***
BVMT-	R 0.61*** 0.58***
MSNQ-	T −0.26** −0.12 −0.11
FSMC	-	T −0.51*** −0.27** −0.29** 0.76***
FSMC-	M −0.55*** −0.25** −0.31** 0.67*** 0.96***
FSMC-	C −0.45*** −0.29** −0.27** 0.78*** 0.97*** 0.87**




*p <	.05;	**p < .01; ***p < .001















SDMT 0.89 0.86 0.86
CVLT-	II 0.83 0.84 0.78
BVMT-	R 0.75 0.71 0.75
MSNQ 0.91 0.89 0.84
FSMC-	T 0.94 0.87 0.72
FSMC-	M 0.92 0.79 0.64
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Unsurprisingly,	MS	 patients	 reported	 significantly	more	 cog-
nitive	complaints	than	the	HCs	on	the	MSNQ.	Altogether	46%	of	




of the patients who reported cognitive complaints did not show 
impairment	on	any	of	the	BICAMS	tests.	The	MSNQ	showed	high	
internal consistency. The correlation between the total score of 
the	MSNQ	 and	 the	 SDMT	was	 negative	 and	 statistically	 signifi-
cant,	whereas	the	correlation	between	the	MSNQ	and	the	CVLT-	II,	
and	 the	 BVMT-	R	were	 statistically	 non-	significant.	 Instead,	 cor-
relations	 between	 the	 total	 score	 of	 the	 MSNQ	 and	 the	 total	
score	as	well	as	sub-	scores	of	the	FSMC,	and	the	CES-	D	were	all	





separately being >	 0.80,	 as	 observed	 also	 previously	 (Benedict	
et	 al.,	 2008;	 Morrow	 et	 al.,	 2010).	 The	 results	 of	 the	 present	
study	confirm	the	earlier	findings	that	the	MSNQ	score	is	related	
to the elevated scores in depression questionnaires (Benedict 
et	 al.,	 2008;	O’Brien	 et	 al.,	 2007)	 and,	 thus,	 should	 be	 used	 to-
gether	with	an	evaluation	of	mood	state.	The	MSNQ	might	better	
serve as a tool to approach this delicate topic than as a screening 
instrument for cognition per se.
MS	patients	reported	significantly	more	fatigue	than	HCs	on	the	
FSMC.	Altogether,	69%	of	the	patients	reported	at	least	mild	overall	
fatigue	 (Penner	 et	 al.,	 2009)	with	 a	 total	 FSMC	 score	 equal	 to	 or	
over	43	points.	Mild	or	worse	motor	fatigue	(motor	sub-	score	≥	22)	
was	 reported	by	77%	and	mild	 or	worse	 cognitive	 fatigue	 (cogni-
tive	sub-	score	≥	22)	by	62%	of	patients.	These	findings	are	 in	 line	
with	 the	 known	 prevalence	 of	 MS	 fatigue,	 which	 is	 up	 to	 83%	
(Manjaly	et	al.,	2019).	The	FSMC	showed	high	internal	consistency	
as	Cronbach's	alpha	was	over	0.95	 for	 the	 total	as	well	 as	 for	 the	
sub-	scales.	Altogether	58%	of	 our	 patients	who	 reported	 at	 least	
mild	cognitive	fatigue	on	the	FSMC	(≥22	points)	showed	impairment	
on	at	 least	one	of	 the	tests	of	 the	BICAMS	battery	and	50%	spe-
cifically	on	the	SDMT.	The	correlations	between	the	total	and	the	
sub-	scores	of	the	FSMC	and	the	SDMT,	the	CVLT-	II	and	the	BVMT-	R	
were	all	 negative	 and	 statistically	 significant.	 In	 contrast,	 the	 cor-
relation	 between	 the	 cognitive	 sub-	score	 of	 the	 FSMC	 and	 the	
MSNQ	was	positive	and	statistically	significant.	The	test–	retest	cor-








tion	procedure	 in	a	 sample	of	65	MS	patients	and	45	HCs,	 tested	
twice within a short interval in controlled study environment. The 
median	duration	of	MS	was	15	years	from	diagnosis	and	the	patient	
reported	disability	score	(PREDSS)	(Kobelt	et	al.,	2006)	was	approx-
imately	 5.0.	 These	 features	 explain	 the	 slightly	 elevated	 cognitive	
impairment rate in our study compared with other studies using the 
BICAMS	for	younger	patients	with	milder	disability.	We	used	the	ex-
isting	 Finnish	 versions	 of	 the	 SDMT	 and	 the	BVMT-	R	which	 both	
showed	appropriate	test–	retest	validity.	The	CVLT-	II	was	translated	


















both questionnaires should be used together with the evaluation of 
mood	state.	More	detailed	validation	of	the	MSNQ	and	the	FSMC	
will	 require	 a	 larger	 sample	 size	 and	an	additional	 fatigue	 scale	 to	
evaluate	the	criterion	validity.	Thus,	the	results	on	the	two	question-
naires have to be considered preliminary.
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